Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Presented at SABCS 2022. December 6-10, 2022 - Lu, Y-S; Mahidin, E IBM; Azim, H
Abstract GS1-10